Ventus Therapeutics Names Dr. Mona Kotecha as Chief Medical Officer Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced the appointment of Mona Kotecha, M.D., as its new Chief Medical Officer…
Alzamend Neuro Advances Alzheimer’s and Psychiatric Disorder Research with Tesla-Developed Head Coil for Phase II Trials Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company dedicated to developing innovative…
Celerion Expands UK Phase 1 Trials at Queen’s University Belfast’s iREACH Health Celerion, a global leader in early clinical research, has announced a strategic agreement to relocate its U.K. Phase…
Stablepharma Secures Prestigious €2.5 Million EIC Accelerator Grant, Recognised Among Europe’s Leading Innovators UK-based biotechnology company Stablepharma Ltd has secured €2.5 million in funding from the highly competitive European Innovation…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs, has announced…
Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a biotechnology company pioneering innovative approaches to harness the natural immune system and cytokine signaling for the treatment of life-threatening…
PharmaJet to Showcase Advantages of Needle-Free Intradermal Delivery at Medical Conference in Ethiopia PharmaJet®, a company dedicated to enhancing the performance and outcomes of injectables through its innovative technology, has…
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in leveraging genomic insights to drive improved health outcomes,…
Galderma’s Nemluvio® Approved in UK & Switzerland for Skin Conditions Galderma, a global leader in dermatology, has announced that its innovative monoclonal antibody treatment, Nemluvio® (nemolizumab), has been granted marketing…
ICC Arbitral Tribunal Decides in Favor of AOP Health in Arbitration over BESREMi® (Ropeginterferon alfa-2b) A tribunal under the International Chamber of Commerce (ICC) issued a partial final award in…
Pneuma Respiratory: Advancing Inhaled Therapeutics to Revolutionize Respiratory Health Pneuma Respiratory, a pioneering med-tech and pharmaceutical company, is breaking new ground in the field of inhaled respiratory therapeutics. With a…
InnoCare Gets Approval for Phase III Study of ICP-248 and Orelabrutinib for First-Line CLL/SLL Therapy in China InnoCare Pharma, a prominent biopharmaceutical company focusing on the treatment of cancer and…